Preparation and characterization of PLGA Nanoparticles containing recombinant core-NS3 Fusion protein of hepatitis C virus as a nano-vaccine candidate
Introduction: Hepatitis C virus (HCV) is one of the most serious causes of cirrhosis, liver cancer and ultimately death, worldwide. The new direct-acting drugs are not accessible for many patients around the world and progress toward new therapeutic and anaphylactic vaccines design has not been fast...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pasteur Institute of Iran
2017-05-01
|
| Series: | Vaccine Research |
| Subjects: | |
| Online Access: | http://vacres.pasteur.ac.ir/article-1-102-en.html |
| _version_ | 1818134455795056640 |
|---|---|
| author | S Hekmat MM Aslani M Shafiee Ardestani MR Aghasadeghi SD Siadat SM Sadat M Mahdavi S Shahbazi F Asgarhalvaee SMM Ghahari F Tohidi |
| author_facet | S Hekmat MM Aslani M Shafiee Ardestani MR Aghasadeghi SD Siadat SM Sadat M Mahdavi S Shahbazi F Asgarhalvaee SMM Ghahari F Tohidi |
| author_sort | S Hekmat |
| collection | DOAJ |
| description | Introduction: Hepatitis C virus (HCV) is one of the most serious causes of cirrhosis, liver cancer and ultimately death, worldwide. The new direct-acting drugs are not accessible for many patients around the world and progress toward new therapeutic and anaphylactic vaccines design has not been fast enough. This study was aimed to prepare and assess a recombinant fusion protein core-NS3 (rC-N) of HCV with the accompaniment of d,l-polylactide-co-glycolide nanoparticles (PLGA NPs) as a nano-conjugated vaccine candidate. Methods: The rC-N protein containing the first domain of core and middle region of NS3 (residues 1095-1384) was loaded into PLGA NPs (rC-N/PLGA NPs) by NHS and DDC (equimolar: 0.5 mM) as conjugating agents. The morphology and average of surface roughness (Ra) of PLGA NPs and rC-N/PLGA NPs were demonstrated by atomic force microscope (AFM). The particle sizes, polydispersity index (PDI) and zeta potential were measured by Zetasizer. Results: The morphology of the nanoparticles was spherical and their surface Ra was measured to be 7.630 nm for PLGA NPs and 15.72 nm for rC-N/PLGA NPs. The average size (160.4 nm), zeta potential (-37.6 mV) and PDI (0.227) were also obtained for rC-N/ PLGA NPs. Conclusion: The surface Ra value of rC-N/PLGA NPs (15.72 nm) which was twice more than PLGA NPs (7.630 nm) confirmed a successful conjugation. The stability of nanoparticles behavior in the colloid was confirmed by the absolute value of zeta potential (|-37.6|= 37.6 mV) of rC-N/PLGA NPs. The spherical morphology, average size < 200, an absolute value of zeta potential > 30 mV, PDI < 0.5 were confirmatory indications that rC-N/PLGA NPs could be considered as vaccine candidate. The rC-N/PLGA NPs construct should be further evaluated via in-vivo challenges and demonstration of targeted delivery to the antigen presenting cells. |
| first_indexed | 2024-12-11T09:08:54Z |
| format | Article |
| id | doaj.art-542358c7449b488f8fd6f23d92eb50f5 |
| institution | Directory Open Access Journal |
| issn | 2383-2819 2423-4923 |
| language | English |
| last_indexed | 2024-12-11T09:08:54Z |
| publishDate | 2017-05-01 |
| publisher | Pasteur Institute of Iran |
| record_format | Article |
| series | Vaccine Research |
| spelling | doaj.art-542358c7449b488f8fd6f23d92eb50f52022-12-22T01:13:33ZengPasteur Institute of IranVaccine Research2383-28192423-49232017-05-01411318Preparation and characterization of PLGA Nanoparticles containing recombinant core-NS3 Fusion protein of hepatitis C virus as a nano-vaccine candidateS Hekmat0MM Aslani1M Shafiee Ardestani2MR Aghasadeghi3SD Siadat4SM Sadat5M Mahdavi6S Shahbazi7F Asgarhalvaee8SMM Ghahari9F Tohidi10 Department of hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. Microbiology Research Center (MRC) Pasteur Institute of Iran, Tehran, Iran./ Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran. Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences. Tehran, Iran. Department of hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. Microbiology Research Center (MRC) Pasteur Institute of Iran, Tehran, Iran./ Department of Mycobacteriology and pulmonary research, Pasteur Institute of Iran, Tehran, Iran. Department of hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. Department of Immunology, Pasteur Institute of Iran, Tehran, Iran. Department of hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. Department of Microbiology, Pharmacotical Science Branch, Islamic Azad University, Tehran, Iran. Department of Immunology, School of Medicine, Mazandaran University of Medical sciences, Sari, Iran. Department of Microbiology, Science and Research Branch, Islamic Azad University, Fars, Iran. Introduction: Hepatitis C virus (HCV) is one of the most serious causes of cirrhosis, liver cancer and ultimately death, worldwide. The new direct-acting drugs are not accessible for many patients around the world and progress toward new therapeutic and anaphylactic vaccines design has not been fast enough. This study was aimed to prepare and assess a recombinant fusion protein core-NS3 (rC-N) of HCV with the accompaniment of d,l-polylactide-co-glycolide nanoparticles (PLGA NPs) as a nano-conjugated vaccine candidate. Methods: The rC-N protein containing the first domain of core and middle region of NS3 (residues 1095-1384) was loaded into PLGA NPs (rC-N/PLGA NPs) by NHS and DDC (equimolar: 0.5 mM) as conjugating agents. The morphology and average of surface roughness (Ra) of PLGA NPs and rC-N/PLGA NPs were demonstrated by atomic force microscope (AFM). The particle sizes, polydispersity index (PDI) and zeta potential were measured by Zetasizer. Results: The morphology of the nanoparticles was spherical and their surface Ra was measured to be 7.630 nm for PLGA NPs and 15.72 nm for rC-N/PLGA NPs. The average size (160.4 nm), zeta potential (-37.6 mV) and PDI (0.227) were also obtained for rC-N/ PLGA NPs. Conclusion: The surface Ra value of rC-N/PLGA NPs (15.72 nm) which was twice more than PLGA NPs (7.630 nm) confirmed a successful conjugation. The stability of nanoparticles behavior in the colloid was confirmed by the absolute value of zeta potential (|-37.6|= 37.6 mV) of rC-N/PLGA NPs. The spherical morphology, average size < 200, an absolute value of zeta potential > 30 mV, PDI < 0.5 were confirmatory indications that rC-N/PLGA NPs could be considered as vaccine candidate. The rC-N/PLGA NPs construct should be further evaluated via in-vivo challenges and demonstration of targeted delivery to the antigen presenting cells.http://vacres.pasteur.ac.ir/article-1-102-en.htmlplga nanoparticlehcv vaccinecorens3fusion protein. |
| spellingShingle | S Hekmat MM Aslani M Shafiee Ardestani MR Aghasadeghi SD Siadat SM Sadat M Mahdavi S Shahbazi F Asgarhalvaee SMM Ghahari F Tohidi Preparation and characterization of PLGA Nanoparticles containing recombinant core-NS3 Fusion protein of hepatitis C virus as a nano-vaccine candidate Vaccine Research plga nanoparticle hcv vaccine core ns3 fusion protein. |
| title | Preparation and characterization of PLGA Nanoparticles containing recombinant core-NS3 Fusion protein of hepatitis C virus as a nano-vaccine candidate |
| title_full | Preparation and characterization of PLGA Nanoparticles containing recombinant core-NS3 Fusion protein of hepatitis C virus as a nano-vaccine candidate |
| title_fullStr | Preparation and characterization of PLGA Nanoparticles containing recombinant core-NS3 Fusion protein of hepatitis C virus as a nano-vaccine candidate |
| title_full_unstemmed | Preparation and characterization of PLGA Nanoparticles containing recombinant core-NS3 Fusion protein of hepatitis C virus as a nano-vaccine candidate |
| title_short | Preparation and characterization of PLGA Nanoparticles containing recombinant core-NS3 Fusion protein of hepatitis C virus as a nano-vaccine candidate |
| title_sort | preparation and characterization of plga nanoparticles containing recombinant core ns3 fusion protein of hepatitis c virus as a nano vaccine candidate |
| topic | plga nanoparticle hcv vaccine core ns3 fusion protein. |
| url | http://vacres.pasteur.ac.ir/article-1-102-en.html |
| work_keys_str_mv | AT shekmat preparationandcharacterizationofplgananoparticlescontainingrecombinantcorens3fusionproteinofhepatitiscvirusasananovaccinecandidate AT mmaslani preparationandcharacterizationofplgananoparticlescontainingrecombinantcorens3fusionproteinofhepatitiscvirusasananovaccinecandidate AT mshafieeardestani preparationandcharacterizationofplgananoparticlescontainingrecombinantcorens3fusionproteinofhepatitiscvirusasananovaccinecandidate AT mraghasadeghi preparationandcharacterizationofplgananoparticlescontainingrecombinantcorens3fusionproteinofhepatitiscvirusasananovaccinecandidate AT sdsiadat preparationandcharacterizationofplgananoparticlescontainingrecombinantcorens3fusionproteinofhepatitiscvirusasananovaccinecandidate AT smsadat preparationandcharacterizationofplgananoparticlescontainingrecombinantcorens3fusionproteinofhepatitiscvirusasananovaccinecandidate AT mmahdavi preparationandcharacterizationofplgananoparticlescontainingrecombinantcorens3fusionproteinofhepatitiscvirusasananovaccinecandidate AT sshahbazi preparationandcharacterizationofplgananoparticlescontainingrecombinantcorens3fusionproteinofhepatitiscvirusasananovaccinecandidate AT fasgarhalvaee preparationandcharacterizationofplgananoparticlescontainingrecombinantcorens3fusionproteinofhepatitiscvirusasananovaccinecandidate AT smmghahari preparationandcharacterizationofplgananoparticlescontainingrecombinantcorens3fusionproteinofhepatitiscvirusasananovaccinecandidate AT ftohidi preparationandcharacterizationofplgananoparticlescontainingrecombinantcorens3fusionproteinofhepatitiscvirusasananovaccinecandidate |